III. A	SYNAGIS WORKSHEET (NL 11-1006) ALL CCS eligible conditions <u>and</u> one of the following			
	Age start of season	Gestation	CONDITION	Requesting MD
1	24 mo and younger	N/A*	CLD that requires medical treatment within 6 mo before anticipated start of seasor	Pediatric Subspecialist or SCC or Ped. and (SCC or Ped. Subspecialist)
2	< 12 mo	28 wk and younger	N/A	Pediatric Subspecialist or SCC or Ped. and (SCC or Ped. Subspecialist)
3	< 6 mo	28 1/7 - 32 wk	N/A	Pediatric Subspecialist or SCC or Ped. and (SCC or Ped. Subspecialist)
4	< 6 mo	32-35 wk	2 or more of the following; Child care attendance School age sibs Exposure to pollutants (tobacco smoke, wood-burning stove, etc.) Congenital Abnormalities of the airways Severe neuromuscular disease	Pediatric Subspecialist or SCC or Ped. and (SCC or Ped. Subspecialist)
5	24 mo and younger	N/A	Cyanotic or Acyanotic CHD	Cardiac SCC or (CCS Pediatrician & Cardiac SCC)
6	N/A	N/A	severe immunodeficiency (eg. SCID, acquired immunodeficiency syndrome, transplant recipients, or children immunocompromised due to chemotherapy)	ID and Immunologic Disorder SCC or, Transplant SCC or, Heme/Onc SCC or, Ped. and (one of these SCCs)
7	48 mo and younger	N/A	at high risk of developing severe complications due to RSV and one of the following: a. Respiratory system disease such as; Cystic fibrosis CLD and requires oxygen therapy, noninvasive, or invasive ventilation Pulmonary hypoplasia Severe upper airway anomalies H/O requiring mech. Vent in the previous RSV season due to RSV disease b. Hemodynamically significant cardiovascular system disease such as; Pulmonary hypertension requiring medical therapy CHF requiring medication for control Cyanotic heart disease c. Children with neuromuscular conditions who have a poor cough due to weak or ineffective respiratory muscles and can not adequately clear respiratory secretions.	Pediatric Subspecialist or SCC or Ped. and (SCC or Ped. Subspecialist)
8	N/A	N/A	Clinical evidence supported by medical literature that the patient has a CCS medically eligible condition that would likely cause significant cardiopulmonary deterioration and hospitalization if the patient developed RSV Infection. (Medical Consultant must review)	CCS Pediatric Subspecialist
III. C	N/A	N/A	premature infants who are only eligible for diagnostic services through HRIF are not eligible for Palivizumab	